What's new

Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised

Mar 17, 2025 - 16:54
 0
Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised
Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised
Read More

Tags:

Previous Article

Orca Bio to seek approval of T cell transplant after positive trial data

Next Article

Quest Nutrition debuts high-protein shake

Related Posts

Orphan designation: [4-(Methyl-1H-pyrazol-4-yl)-benzyl]-(6[7-(3-pyrrolidin-1-yl-propoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl]-amine Treatment of gastrointestinal stromal tumours, 16/01/2025 Positive

Orphan designation: [4-(Methyl-1H-pyrazol-4-yl)-benzyl]...

Feb 20, 2025  0

Human medicines European public assessment report (EPAR): Zolsketil pegylated liposomal, doxorubicin, Date of authorisation: 31/05/2022, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 13, 2025  0

Clinical Trials Information System

Clinical Trials Information System

Feb 24, 2025  0